Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Ra Capital Management, L.P. Purchases 996 Shares

Posted by Alphonse Anthony on May 22nd, 2026

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) major shareholder Ra Capital Management, L.P. acquired 996 shares of the stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $24.94 per share, for a total transaction of $24,840.24. Following the completion of the transaction, the insider owned 6,376,968 shares in the company, valued at approximately $159,041,581.92. This represents a 0.02% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

On Tuesday, May 19th, Ra Capital Management, L.P. acquired 3,802 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.97 per share, for a total transaction of $94,935.94.
On Tuesday, May 12th, Ra Capital Management, L.P. purchased 6,387 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.90 per share, for a total transaction of $159,036.30.
On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.81 per share, for a total transaction of $989,149.89.
On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.98 per share, for a total transaction of $37,045.34.
On Thursday, May 7th, Ra Capital Management, L.P. purchased 9,906 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.46 per share, for a total transaction of $242,300.76.
On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.60 per share, with a total value of $1,673,242.80.
On Tuesday, May 5th, Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.63 per share, with a total value of $2,399,232.93.
On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Stock Down 0.6%

Shares of NASDAQ:COAG opened at $26.30 on Friday. Hemab Therapeutics Holdings, Inc. has a 1 year low of $23.00 and a 1 year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last released its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th.

Read Our Latest Analysis on Hemab Therapeutics

Hemab Therapeutics Company Profile

(Get Free Report)

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.